Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16737686 | 1.00 | PTGDR2 (0.33) | PTGDR2AAK1MGLLCACNA1HCHRNB2 | |
| SCHEMBL16738020 | 0.92 | HTT (0.34) | PTGDR2AAK1MGLLCHRNB2CHRNB4 | |
| SCHEMBL16737793 | 0.91 | PTGDR2 (0.33) | PTGDR2AAK1 | |
| SCHEMBL16737792 | 0.91 | PTGDR2 (0.33) | PTGDR2AAK1 | |
| SCHEMBL16737899 | 0.84 | CTSL (0.32) | PTGDR2AAK1NPC1RAB9A | |
| SCHEMBL16737900 | 0.84 | CTSL (0.32) | PTGDR2AAK1NPC1RAB9A | |
| SCHEMBL16737939 | 0.84 | CTSL (0.32) | PTGDR2AAK1NPC1RAB9A | |
| SCHEMBL16747640 | 0.80 | HTT (0.37) | PTGDR2AAK1MGLLNPC1RAB9A | |
| SCHEMBL16737797 | 0.78 | CTSL (0.32) | PTGDR2AAK1NPC1RAB9A | |
| SCHEMBL16737879 | 0.78 | CTSL (0.32) | PTGDR2AAK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | PTGDR2 2234/4885AAK1 3599/4885MGLL 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.